Ventripoint Diagnostics this week announced the publication of a study of its VMS heart analysis system, touting that the system’s functionality.
The study, undertaken by the cardiology group at London’s Royal Free Hospital, was published in the journal Echocardiography.
Results from the study indicate that the system was able to follow patients with enlarged right ventricles and accurately measure small but significant changes in volume and function, Ventripoint said.
The company said that the system’s ability to monitor clinical outcomes after therapy has been initiated is important in determining if therapy is working well or if a new therapeutic approach is required.
“Ventricular remodeling in PAH can be differentiated into two patterns: adaptive remodeling with concentric hypertrophy and preserved function, and maladaptive remodeling with eccentric hypertrophy and worsening function. Our study shows that within several months a change from one pattern to the other can occur with medical therapy. 2DKBR can be reliably used in a busy clinical setting to follow-up right-ventricular indices in pulmonary hypertension,” study authors wrote, according to a press release.